TOP2A and ovarian small cell carcinoma: In addition, by IHC, 100 % of SCCO patients (7/7), 92 % of SCCO-HT patients (11/12), and 69 % of NET-O patients (11/16) expressed TOP2A, while 95 % of patients with SCLC (52/55) expressed TOP2A.